Pharmaceutical

RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for RPT904 to treat various allergic conditions.

Dec 25, 2024 - 06:00
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for RPT904 to treat various allergic conditions.
Read the original article

Tags:

Previous Article

Novo gets the green light for once-daily haemophilia drug following setbacks 

Next Article

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Former Pear Therapeutics executives start new VC firm, with biotech veteran Bob Langer as adviser

STAT+: Former Pear Therapeutics executives start new VC...

Aug 23, 2023

CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cel...

Aug 10, 2023

How hybrid models and tech are shaping the future of clinical research 

How hybrid models and tech are shaping the future of cl...

Nov 3, 2024